Newsletter Tool

Today’s Big News

Nov 14, 2024

Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat

Kronos shelves sole remaining clinical asset over neurological side effects

BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1

Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial

Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study

Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval

Gura's weekly amylin obesity asset well tolerated, tied to weight loss in phase 1 trial

Featured

Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat

By Nick Paul Taylor

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.

Kronos shelves sole remaining clinical asset over neurological side effects

By James Waldron

The clock is ticking for Kronos Bio after the biotech discontinued its last remaining clinical-stage asset over neurological adverse events.

BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1

By Nick Paul Taylor

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic lupus erythematosus, providing further evidence that the emerging class of candidates can reset the immune system.

Vaccinating Against Cancer Cells and Reprogramming the Tumor Microenvironment That Protects Them

Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial

By James Waldron

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its immune checkpoint inhibitor though phase 2.

Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study

By Gabrielle Masson

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial.

Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval

By James Waldron

Allogene has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb.

Gura's weekly amylin obesity asset well tolerated, tied to weight loss in phase 1 trial

By Gabrielle Masson

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection also linked to weight reduction.

In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex

By Angus Liu

GSK’s £3 billion sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key head-to-head patient survival win against J&J’s Darzalex

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years

By Fraiser Kansteiner

In the three-year SURMOUNT-1 trial, three pooled doses of tirzepatide (5 mg, 10 mg and 15 mg) curbed the risk of disease progression to type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said Wednesday.

Say goodbye to BeiGene as the oncology biopharma becomes BeOne Medicines in rebrand

By Ben Adams

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal.

Fierce podcasts

Don’t miss an episode

Closing gaps in clinical trial infrastructure

In this week’s episode of “Podnosis,” we’re diving deep into the current landscape of clinical trials in the U.S.

Best practices for health system-startup partnerships

Closing the menopause care gap

Resources

Whitepaper

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific